Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«PAPPA

Below is an extended PAPPA publications listing. Click here to return to the gene page.

Gene Information from Publications

Publication Link Summary of findings
18089325 PAPP-A level is elevated in renal transplant patients and high levels of PAPP-A may be a prognostic marker associated with high serum levels of urea, creatinine, uric acid, and C-reactive protein.
17509577 Maternal serum PAPP-A levels in the late first trimester of pregnancy are associated with subsequent fetal growth,both physiologic variation and abnormal growth.
17700210 PAPP-A IVS6+95 C allele is an independent risk factor for acute myocardial infarction even after adjustment for traditional risk factors.
17437322 Maternal systemic lupus erythematosus does not affect first trimester level.
15647258 the proform of eosinophil major basic protein inhibits the proteolytic activity of PAPP-A
16963045 Preliminary evidence suggests that first-trimester uterine artery Doppler measurements do not correlate with maternal serum levels of free beta-hCG and PAPP-A.
17145752 PAPP-A requires the formation of intermolecular proteinase-inhibitor disulfide bonds and glycosaminoglycan covalently bound to the inhibitor
11897673 phorbol ester tumor promoters and simian virus 40 transformation regulate IGFBP-4 proteolysis in human fibroblasts through induction of a novel inhibitor of PAPP-A, pro-MBP
12524241 Elevated serum PAPP-A levels represent a potential marker of the degree of echogenicity of carotid atherosclerotic plaques in asymptomatic hyperlipidemic patients at high cardiovascular risk.
15262980 PAPPA Lin12-notch repeats bind calcium and determine its proteolytic specificity
16086443 maternal serum PAPP-A at 11-13(+6) of gestation is significantly lower in adverse pregnancy outcomes
17516846 Phage display was used to discover fully human antibody inhibitors of PAPP-A activity towards IGFBP4 cleavage
15146551 PAPP-A and proMBP are regulated in malignant ovarian epithelial cells,altering IGFBP-4 proteolysis and local regulation of IGF availability
14657012 PAPP-A expression is regulated by inflammatory cytokines in adult human fibroblasts, with functional consequences on IGFBP-4 protease activity and IGF-I bioavailability
16388849 We suggest that PPARgamma-mediated inhibition of PAPP-A might decrease the amount of bioactive IGFII, a factor known to promote trophoblast invasion.
15919757 PAPP-A functions in the formation of mineralized tissues through direct up-regulation of key genes and is involved in the formation of new blood vessels, which is essential for proper bone regeneration
12414897 data demonstrate the presence of an IGF-II- and metal-dependent IGFBP-4 protease activity in human trophoblast plasma membranes, identified as PAPP-A
15305104 women who experienced spontaneous abortions had significantly different mean PAPP-A serum levels at 10(+1) to 14(+6) weeks gestation
14988014 Proform of eosinophil major basic protein forms a covalent complex with PAPPA in which PAPPA is inhibited.
15754336 findings underscore a novel mechanism whereby glucocorticoids increase IGF responses in bone cells via PAPP-A-induced IGFBP-4 proteolysis
12087395 association of maternal PAPP-A levels and fetal growth/birth weight
14530192 Plasma PAPP-A, a zinc-binding matrix metalloproteinase, is a strong independent predictor of ischemic cardiac events and need of revascularization in patients who present with suspected myocardial infarction but remain troponin negative
12370176 IGF bioactivity is regulated by reversible cell surface binding of PAPP-A, which in turn is regulated by proMBP
16959807 PAPP-A may be involved in the regulation of bone development in the first trimester.
17237617 We demonstrated that after successful TX, PAPP-A and sRAGE decrease and early chronic vascular changes in the kidney TX are associated with elevation of their serum levels.
12421832 PAPP-A's structure is described, and its ability to dimerize and to bind to pro-major basic protein with disulfide bonds explained
12241545 substrate specificity of the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) assessed by mutagenesis and analysis of synthetic peptides
12213189 the PAPP-A mRNA level in mouse placenta was lower compared to that in human placenta by at least two orders of magnitude
16115888 PAPP-A increased the proliferation and differentiation of myoblasts, its myogenic effect is governed by its proteolytic activity, and it promotes skeletal myogenesis by increasing the amount of free IGFs.
12817760 TGF-beta and IGF-II in the bone microenvironment coordinately amplify IGF-I bioavailability through controlled IGFBP-4 protease, which may be a means to promote bone formation.
17177834 the IGF system may have a limited role in the pathogenesis of GCT with PAPP-A subserving a function other than IGFBP-4 proteolysis
17314100 PAPP-A2 LNR1-2, but not LNR3, are functionally conserved with respect to insulin-like growth factor -binding proteins proteolysis
17565927 PAPP-A may contribute to airway smooth muscle hyperplasia
11914564 Fetal trisomies 21, 18, and 13 are associated with a reduction in second-trimester maternal PAPP-A levels
14705967 Partially purified PAPP-A400 exhibited a 4-fold reduction in IGFBP-4 proteolytic activity compared with PAPP-A470. A novel mechanism, conversion of PAPP-A470 to the less-active PAPP-A400, could account for the TPA-induced suppression of PAPP-A activity.
12970325 PAPP-A may play an important role in an integrated insulin-like growth factor system in wound healing and tissue remodeling in vivo

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.